Thursday, October 7th, 2008, 9:00 am ET
News Release
FOR IMMEDIATE RELEASE
Eden Spine receives CE Mark for its nonfusion
Wellex™ interspinous process medical device
“Our device fills the gap between conservative care and fusion surgery
to treat early-stage degenerative disc disease.”
Guillaume Viallaneix, CEO, Eden Spine
LAKE MARY, Fla., Oct. 7, 2008—Eden Spine (www.edenspine.com) announced today that it has received CE Mark approval for its proprietary interspinous medical device, the Wellex™. Developed in collaboration with Dr. Jean-Marc Fuentes from France, the Wellex is based on two decades of clinical experience with nonfusion devices. “The Wellex is a compressible dynamic extension controller that not only relieves pain but also positively affects the long-term health of the segment,” said Dr. Fuentes, “through its ability to dynamically control extension while protecting and maintaining the neutral zone.”
Biomechanically, the Wellex maintains flexion, axial rotation and lateral bending but, more importantly, is not an extension blocker. Rather, it controls extension dynamically, thereby positively affecting the neutral zone and reducing disc and facet loading. Multi-level implantations are possible.
 “The Wellex Interspinous Process Technology aims at perfecting the balance between motion and stability by restoring the posterior tension band, the facet congruence and the foraminal height,” explained Mourad Ben Mokhtar, head of Eden Spine’s research and developments efforts. “Its unique characteristics establish it as the latest generation of extension controllers, positioning it to be the gold standard for spinal patients who do not respond positively to conservative treatment, who are not willing to suffer the consequences of a fusion, and who are in need of pain relief from spinal stenosis.”
“Considering that spinal stenosis is the number-one preoperative diagnosis for adults over 65 in the U.S., and that an aging population is the number-one reason for the increase in spinal stenosis, leading to projections that by 2026, 20 percent of the U.S. population—or 65 million people—will be over the age of 65, it is clear that the Wellex represents a significant opportunity for Eden Spine to positively impact patient care in the years to come,” said Guillaume Viallaneix, CEO.
Eden Spine LLC, a privately held spine company, is creating shareholder value by simultaneously emphasizing Sales and R&D. As an R&D organization focused on motion preservation technologies, Eden Spine has developed three new-generation, nonfusion technologies—the WellDisc total disc replacement; the FX 1 Dynamic Rod; and, the Wellex Interspisous Technology. As a Sales & Marketing organization, Eden Spine distributes in the U.S. a comprehensive range of FDA-cleared fusion technologies.
####
Eden Spine LLC is a privately held spinal organization headquartered in Lake Mary, Florida. As a developer of motion preservation technologies, specialized in the area of Posterior Dynamic Stabilization, the Eden Spine Group has put together an international team of scientific personalities dedicated to turning imaginative ideas into leading spinal solutions. The goal is to simultaneously address the issue of pain and functionality, thus improving patient care. Eden Spine's core values reflect the energy and spirit of a company with solid moral foundations articulated around a code of behavior that guides us with integrity and passion.
information contact:
Guillaume Viallaneix, CEO, Phone:     407... - Fax: 407-264-8303 - e-mail:
CLOAKING
Headquarters: Eden Spine, LLC - 801 International Parkway - 5th Floor - Lake Mary, FL 32746
Sales & Marketing Offices: Eden Spine LLC - 7301 Carmel Executive Park - Suite 320 - Charlotte, NC 28226
European R&D Offices: Eden Spine Europe SA - Bd Helevetique, 36 - 1207 Geneva- Switzerland
Web address: http://www.EdenSpine.com
|
